Indivior PLC: The Nomination Committee Has Started a Search for a Successor
Indivior PLC: Hetherington Has Been a Board Member for Five Years
Indivior PLC Chair Graham Hetherington To Retire At the End of 2024
Indivior PLC Announces Total Voting Rights
Indivior Advances Share Repurchase Plan
Express News | Indivior PLC : Craig-Hallum Cuts Target Price to $20 From $24
Top 3 Health Care Stocks That May Explode This Month
Northland Securities Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $25
Northland Securities analyst Carl Byrnes maintains $Indivior(INDV.US)$ with a buy rating, and adjusts the target price from $35 to $25.According to TipRanks data, the analyst has a success rate of 35.
Indivior Price Target Maintained With a $22.00/Share by Piper Sandler
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $22
Piper Sandler analyst David Amsellem maintains $Indivior(INDV.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 45.0% and a
Piper Sandler Sticks to Its Buy Rating for Indivior (INDV)
BlackRock Reduces Stake in Indivior Below 5%
Stifel Initiates Indivior(INDV.US) With Buy Rating, Announces Target Price $28.48
Stifel analyst Christian Glennie initiates coverage on $Indivior(INDV.US)$ with a buy rating, and sets the target price at $28.48.According to TipRanks data, the analyst has a success rate of 33.3%
Maintaining Buy Rating: Indivior's Growth Prospects and Undervaluation Despite Near-Term Challenges
Indivior PLC Advances Share Repurchase Program
Smith & Wesson Brands Reports Downbeat Results, Joins Planet Labs PBC, Broadcom And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Deutsche Bank Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $20.34
Deutsche Bank analyst Paul Cuddon maintains $Indivior(INDV.US)$ with a buy rating, and maintains the target price at $20.34.According to TipRanks data, the analyst has a success rate of 33.3% and a
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option
Indivior to Forgo Option to License Aelis Farma's Cannabis Use Disorder Drug